ART5 is designed to address the most common root cause of ADPKD by targeting PKD1, potentially restoring PC1 production in approximately 85% of patientsFirst-in-human SAD study in healthy volunteers ...
About one in every 25 Australians under the age of 18 has been the victim or knows a victim of artificial ...
Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program. KT-621 parallel Phase 2b trials advancing in AD and asthma, with data e ...
VANCOUVER, BC / ACCESS Newswire / July 6, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren't often backed by appropriate clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results